| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $68,406,740 | 31 | 100 |
| Smith Mark Douglas | director | 0 | $0 | 1 | $266,746 | $-266,746 |
| RIEDEL NORBERT G | director | 0 | $0 | 1 | $655,680 | $-655,680 |
| GALA RENEE D | President & CEO | 0 | $0 | 2 | $958,860 | $-958,860 |
| McSharry Heather Ann | director | 0 | $0 | 2 | $1.09M | $-1.09M |
| Henderson Mary Elizabeth | SVP, Technical Operations | 0 | $0 | 2 | $1.42M | $-1.42M |
| Pearce Samantha | EVP, Chief Commercial Officer | 0 | $0 | 1 | $1.63M | $-1.63M |
| Winningham Rick E | director | 0 | $0 | 2 | $1.66M | $-1.66M |
| Carr Patricia | SVP, Chief Accounting Officer | 0 | $0 | 5 | $2.46M | $-2.46M |
| Patil Neena M | EVP & Chief Legal Officer | 0 | $0 | 4 | $11.5M | $-11.5M |
| Iannone Robert | EVP, Global Head of R&D & CMO | 0 | $0 | 2 | $20.41M | $-20.41M |
| COZADD BRUCE C | director | 0 | $0 | 9 | $26.36M | $-26.36M |
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic …
Over the last 12 months, insiders at Jazz Pharmaceuticals plc have bought $0 and sold $68.41M worth of Jazz Pharmaceuticals plc stock.
On average, over the past 5 years, insiders at Jazz Pharmaceuticals plc have bought $5.71M and sold $20.87M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,621 shares for transaction amount of $166,962 was made by Mulligan Seamus (director) on 2025‑05‑12.
| 2026-10-06 | Sale | GALA RENEE D | President & CEO | 2,000 0.0033% | $236.40 | $472,800 | -7.57% | |
| 2026-10-01 | Sale | COZADD BRUCE C | director | 6,000 0.0094% | $230.33 | $1.38M | -7.98% | |
| 2026-09-10 | Sale | Patil Neena M | EVP & Chief Legal Officer | 1,200 0.0019% | $240.94 | $289,128 | -4.16% | |
| 2026-09-08 | Sale | GALA RENEE D | President & CEO | 2,000 0.0032% | $243.03 | $486,060 | -3.66% | |
| 2026-09-01 | Sale | COZADD BRUCE C | director | 6,000 0.0098% | $250.13 | $1.5M | -4.83% | |
| 2026-08-27 | Sale | Iannone Robert | EVP, Global Head of R&D & CMO | 76,921 0.121% | $249.70 | $19.21M | -7.20% | |
| 2026-08-03 | Sale | COZADD BRUCE C | director | 6,000 0.0095% | $252.98 | $1.52M | -4.38% | |
| 2026-07-01 | Sale | COZADD BRUCE C | director | 6,000 0.0097% | $240.47 | $1.44M | +2.56% | |
| 2026-06-15 | Sale | Smith Mark Douglas | director | 1,157 0.0018% | $230.55 | $266,746 | +4.58% | |
| 2026-06-10 | Sale | Patil Neena M | EVP & Chief Legal Officer | 1,200 0.0019% | $231.83 | $278,196 | +4.88% | |
| 2026-05-28 | Sale | Patil Neena M | EVP & Chief Legal Officer | 1,192 0.0019% | $236.97 | $282,468 | +1.99% | |
| 2026-05-28 | Sale | Pearce Samantha | EVP, Chief Commercial Officer | 6,907 0.011% | $235.41 | $1.63M | +1.99% | |
| 2026-05-22 | Sale | McSharry Heather Ann | director | 2,000 0.0032% | $241.00 | $482,000 | -0.21% | |
| 2026-05-22 | Sale | Winningham Rick E | director | 2,741 0.0044% | $241.57 | $662,143 | -0.21% | |
| 2026-05-01 | Sale | COZADD BRUCE C | director | 6,000 0.0096% | $203.33 | $1.22M | +17.32% | |
| 2026-04-01 | Sale | COZADD BRUCE C | director | 6,000 0.0099% | $190.50 | $1.14M | +25.18% | |
| 2026-03-09 | Sale | Carr Patricia | SVP, Chief Accounting Officer | 1,287 0.0021% | $182.94 | $235,444 | +24.84% | |
| 2026-03-03 | Sale | COZADD BRUCE C | director | 6,000 0.0095% | $186.44 | $1.12M | +23.81% | |
| 2026-02-27 | Sale | Carr Patricia | SVP, Chief Accounting Officer | 1,117 0.0018% | $190.91 | $213,243 | +21.56% | |
| 2026-02-27 | Sale | RIEDEL NORBERT G | director | 3,415 0.0057% | $192.00 | $655,680 | +21.56% |
| COZADD BRUCE C | director | 345875 0.5328% | $79.46M | 1 | 124 | +194.39% |
| MICHELSON MICHAEL W | director | 9906501 15.2608% | $2.28B | 1 | 0 | <0.0001% |
| RAETHER PAUL E | 9906501 15.2608% | $2.28B | 1 | 0 | <0.0001% | |
| KKR JP LLC | 9906501 15.2608% | $2.28B | 1 | 0 | <0.0001% | |
| BRIDGER MANAGEMENT LLC | 10 percent owner | 2667050 4.1086% | $612.73M | 9 | 0 | <0.0001% |
| COLELLA SAMUEL D | director | 1488676 2.2933% | $342.01M | 1 | 0 | <0.0001% |
| TANANBAUM JAMES B | director | 1403129 2.1615% | $322.35M | 1 | 0 | <0.0001% |
| Saks Samuel R | Chief Executive Officer | 347001 0.5346% | $79.72M | 3 | 0 | <0.0001% |
| MYERS ROBERT M | President | 152206 0.2345% | $34.97M | 1 | 3 | +175.25% |
| FALBERG KATHRYN E | EVP and CFO | 124721 0.1921% | $28.65M | 3 | 9 | +139.43% |
| Mulligan Seamus | director | 101621 0.1565% | $23.35M | 5 | 18 | +27.1% |
| SEBULSKY ALAN | director | 54355 0.0837% | $12.49M | 2 | 1 | +8.7% |
| Johnson Philip L | EVP & Chief Financial Officer | 27932 0.043% | $6.42M | 1 | 0 | <0.0001% |
| CRESSEY BRYAN C | director | 27631 0.0426% | $6.35M | 1 | 2 | <0.0001% |
| O'Keefe Kenneth W | director | 24723 0.0381% | $5.68M | 3 | 15 | <0.0001% |
| ENRIGHT PATRICK G | director | 20946 0.0323% | $4.81M | 3 | 47 | +41.06% |
| Smith Karen L. | Global Head of R&D and CMO | 14182 0.0218% | $3.26M | 3 | 0 | <0.0001% |
$961,890,236 | 276 | 22.46% | $23.97B | |
$273,531,368 | 93 | 38.24% | $9.16B | |
$2,765,836 | 72 | 20.00% | $10.77B | |
$108,876,545 | 67 | 72.81% | $14.6B | |
$11,991,408 | 51 | 18.36% | $22.91B |
| Increased Positions | 316 | +55.24% | 9M | +14.8% |
| Decreased Positions | 248 | -43.36% | 8M | -12.85% |
| New Positions | 129 | New | 1M | New |
| Sold Out Positions | 56 | Sold Out | 530,752 | Sold Out |
| Total Postitions | 640 | +11.89% | 62M | +1.94% |
| Vanguard Group Inc | $1.02M | 9.68% | 5.91M | -183,927 | -3.02% | 2025-09-30 |
| Blackrock, Inc. | $962,595.00 | 9.11% | 5.56M | -240,404 | -4.14% | 2025-09-30 |
| Dimensional Fund Advisors Lp | $491,166.00 | 4.65% | 2.84M | +298,815 | +11.77% | 2025-09-30 |
| Capital World Investors | $442,375.00 | 4.19% | 2.55M | +10,345 | +0.41% | 2025-09-30 |
| Lsv Asset Management | $434,928.00 | 4.12% | 2.51M | -41,884 | -1.64% | 2025-09-30 |
| State Street Corp | $323,424.00 | 3.06% | 1.87M | -67,499 | -3.49% | 2025-09-30 |
| Jpmorgan Chase & Co | $323,299.00 | 3.06% | 1.87M | +145,865 | +8.47% | 2025-09-30 |
| Ameriprise Financial Inc | $319,887.00 | 3.03% | 1.85M | -19,944 | -1.07% | 2025-09-30 |
| Ecor1 Capital, Llc | $295,475.00 | 2.8% | 1.71M | 0 | 0% | 2025-09-30 |
| Fuller & Thaler Asset Management, Inc. | $281,565.00 | 2.67% | 1.63M | -2,823 | -0.17% | 2025-09-30 |